Charles River plays an integral role in the preclinical discovery and development of new therapies and treatments for central nervous system (CNS) and peripheral nervous system (PNS) diseases by providing non-GLP in vivo and in vitro studies for efficacy and mechanism of action of compounds and devices. Focusing on neurology and psychiatry, our Finland site’s in vivo pharmacology capabilities include small animal imaging (MRI/MRS, PET-CT, SPECT-CT), behavioral testing, efficacy testing, histology and immunohistochemical analysis including stereology. The site is outfitted to handle high-volume, comprehensive preclinical studies in small animals.

Download our Finland At-a-Glance datasheet for more information on the facility and capabilities.